NCT03679975 - Riluzole Oral Soluble Film (ROSF) Swallowing Safety in Amyotrophic Lateral Sclerosis (ALS) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

April 4, 2018

Primary Completion Date

September 26, 2018

Study Completion Date

December 21, 2018

Conditions

Amyotrophic Lateral Sclerosis

Interventions

DRUG

Riluzole Oral Soluble film (ROSF) 50 mg

Enrolled subjects underwent an instrumental evaluation of swallowing safety before and after administration of a single dose of the ROSF formulation containing 50 mg of riluzole.

Trial Locations (1)

32607

University of Florida Center for Movement Disorders & Neuroscience, Gainesville